Transcription of Implementation Process Article 5(3) Nitrosamine
{{id}} {{{paragraph}}}
Example: bankruptcy
Implementation Process Article 5(3) Nitrosamine
Official address Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands An agency of the European Union Address for visits and deliveries Refer to Send us a question Go to Telephone +31 (0)88 781 6000 European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/425645/2020 22 February 2021 European Medicines Regulatory Network approach for the Implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for Nitrosamine impurities in human medicines European Medicines Regulatory Network approach for the Implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for Nitrosamine impurities in human medicines EMA/425645/2020 Page 2/14 Table of contents 1.
mitigated as much as possible and shall be at or below the acceptable intake (AI), based on the ICH M7(R1) guideline and calculated considering a lifetime daily exposure. This should be achieved by an appropriate control strategy and by the design or adaptation of the manufacturing processes aiming to
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: